新四联疗法治疗幽门螺杆菌相关性胃炎疗效分析

摘要

Objective To explore the effect of new quadruple therapy for Helicobacter pylori associated gastritis.Methods Four hundred and seventy-two patients were randomly divided into two groups:the control group (n=244,colloidal bismuth pectin combined with triple therapy),the treatment group (n=228,Jinghuaweikang capsules combined with triple therapy).The adverse drug reaction,H.pylori eradication rate and clinical symptoms were observed.Results Adverse reactions occurred in 13 patients in the control group and one patient in the treatment group,with statistically significant difference between the two groups (P＜0.01).H.Pylori eradication rate of the control group [89.18％ (206/231)] was higher than that of the treatment group [85.46％ (194/227)],with no statistically significant difference (P＞0.05).The improvement of clinical symptoms in the treatment group at the end of the first week and the eighth week was significantly better than that in the control group (P＜0.05).Conclusion New quadruple therapy has similar clinical efficacy with bismuth-containing quadruple therapy,but is safer and more effective.%目的 探讨荆花胃康胶丸联合三联疗法组成的新四联疗法治疗幽门螺杆菌(HP)相关性胃炎的疗效.方法 472例H.Pylori相关性胃炎患者随机分成两组.对照组244例采用胶体果胶铋联合三联疗法治疗;治疗组228例采用荆花胃康胶丸联合三联疗法治疗.观察两组患者的药物不良反应、H.Pylori根除率及临床症状改善情况.结果 对照组和治疗组各有13例和1例患者出现不良反应(P＜0.01);H.Pylori根除率分别为89.18％ (206/231)和85.46％ (194/227)(x2=1.429,P＞0.05).治疗组在治疗后1周末、8周末的临床症状改善情况明显优于对照组(Uc=2.387、2.413,P＜0.05).结论 新四联疗法在H.pylori根除率上与含铋四联疗法接近,但在药物安全性及临床症状的改善方面明显优于后者,值得推广使用.